RT Journal Article
SR Electronic
T1 Relationship between blood eosinophil count (Eos), clinical characteristics and mortality of patients with COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4614
DO 10.1183/13993003.congress-2016.PA4614
VO 48
IS suppl 60
A1 Zysman, Maeva
A1 Burgel, Pierre Regis
A1 Paillasseur, Jean Louis
A1 Chanez, Pascal
A1 Caillaud, Denis
A1 Escamilla, Roger
A1 Court Fortune, Isabelle
A1 Nesme Meyer, Pascal
A1 Brinchault Rabin, Graziella
A1 Deslee, Gaetan
A1 Perez, Thierry
A1 Pinet, Christophe
A1 Roche, Nicolas
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA4614.abstract
AB Background: Several studies suggest that, in patients with COPD, Eos is associated with (i) exacerbation frequency and (ii) the effect of inhaled corticosteroid for exacerbation prevention.Aim: To determine whether Eos defines patients' groups exhibiting attributes of COPD clinical phenotypes, we compared the clinical features and mortality rate between COPD patients with ≥2% (Eos+) and <2% (Eos-) blood eosinophils in the Initiatives BPCO French cohort.Methods: The following data were collected at inclusion: medical and smoking history, occupational exposures, dyspnea, cough and sputum production, exacerbations in the previous year, history of allergy and asthma, nasal symptoms, BMI, SGRQ score, post-bronchodilator spirometry and plethysmography, comorbidities, CRP and medications. Three-year survival was available for all patients. BOD and ADO scores were calculated.Results: Eos was available in 458 patients (mean age: 62 years, 72% male, mean FEV1: 51%), including 235 Eos+ patients (49%). No difference between Eos+ and Eos- groups was observed in univariate analyses except for diabetes (17% in Eos-, 8% in Eos+, p=0.02) and SGRQ score (mean, 48 units in Eos -, 40 units in Eos+, p=0.007). In particular, there was no difference in term of exacerbations rate (mean, 1.6/patient/year) or history of asthma (15% of the population). Three-year mortality rate was 17% in Eos- vs 13% in Eos+ (NS).Conclusion: Apart from differences in health-related quality of life and frequency of diabetes (which warrant further investigation), Eos+ COPD patients exhibit no specific clinical characteristic, especially regarding symptoms, lung function, exacerbations and prognosis.